Clinical Trial Update: Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

This is a clinical trial update on a Phase 1/2 study evaluating pamiparib plus surufatinib for platinum-resistant ovarian cancer and related peritoneal-ovarian …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Pamiparib (pamiparib)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Ovarian Cancer, Ovarian Carcinoma | Phase 1, Phase 2 | Status: COMPLETED